Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions
Open Access
- 29 February 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (5) , 1009-1018
Abstract
It remains unclear how localized radiotherapy for cancer metastases can occasionally elicit a systemic antitumor effect, known as the abscopal effect, but historically, it has been speculated to reflect the generation of a host immunotherapeutic response. The ability to purposefully and reliably induce abscopal effects in metastatic tumors could meet many unmet clinical needs. Here, we describe a mathematical model that incorporates physiologic information about T-cell trafficking to estimate the distribution of focal therapy–activated T cells between metastatic lesions. We integrated a dynamic model of tumor–immune interactions with systemic T-cell trafficking patterns to simulate the development of metastases. In virtual case studies, we found that the dissemination of activated T cells among multiple metastatic sites is complex and not intuitively predictable. Furthermore, we show that not all metastatic sites participate in systemic immune surveillance equally, and therefore the success in triggering the abscopal effect depends, at least in part, on which metastatic site is selected for localized therapy. Moreover, simulations revealed that seeding new metastatic sites may accelerate the growth of the primary tumor, because T-cell responses are partially diverted to the developing metastases, but the removal of the primary tumor can also favor the rapid growth of preexisting metastatic lesions. Collectively, our work provides the framework to prospectively identify anatomically defined focal therapy targets that are most likely to trigger an immune-mediated abscopal response and therefore may inform personalized treatment strategies in patients with metastatic disease. Cancer Res; 76(5); 1009–18. ©2016 AACR.Keywords
All Related Versions
Funding Information
- DeBartolo Family Personalized Medicine Institute Pilot Research Awards in Personalized Medicine (PRAPM). (09-33504-14-05, 09-33000-15-03)
This publication has 43 references indexed in Scilit:
- Cancer treatment and survivorship statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal PregnancyClinical Pharmacokinetics, 2012
- Clinical opportunities in combining immunotherapy with radiation therapyFrontiers in Oncology, 2012
- The Confluence of Stereotactic Ablative Radiotherapy and Tumor ImmunologyJournal of Immunology Research, 2011
- Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical ModelsPLOS ONE, 2010
- Conductive interstitial thermal therapy (CITT) inhibits recurrence and metastasis in rabbit VX2 carcinoma modelInternational Journal of Hyperthermia, 2009
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Abscopal effect of radiation in papillary adenocarcinomaBritish Journal of Radiology, 1973